A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive disorder (MDD) who have not responded adequately ...

has accepted for review the New Drug Application (NDA) for bumetanide nasal spray (RSQ-777) for the treatment of edema associated with congestive heart failure, as well as hepatic and renal disease.

Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...

An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...